Flex Pharma Inc (FLKS.OQ)
22 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|48||2017||Chairman of the Board|
|59||2017||President, Chief Executive Officer, Director|
|45||2016||Chief Financial Officer, Treasurer|
|54||2015||Chief Operating Officer|
|42||2014||Vice President - Research & Development|
- BRIEF-Flex Pharma Reports Q1 Loss Per Share $0.46
- BRIEF-Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis
- BRIEF-Flex Pharma Reports Q4 Loss Per Share $0.46
- BRIEF-Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business
- BRIEF-Flex Pharma Inc - Completed Enrollment In Its Phase 2 Exploratory Spasticity Study In Multiple Sclerosis With Approximately 50 Patients In Australia